Transtiretina e Proteina legante il retinolo 4: una valutazione analitica del metodo immunonefelometrico

AUTORI

ABSTRACT

Transthyretin and Retinol binding protein 4: analytical evaluation of the immunonephelometric method

Introduction: transthyretin cardiac amyloidosis (ATTR-CA) is a progressive disease in which circulating levels of TTR contribute to risk stratification of disease progression and represent a biomarker of response to therapy. Aim of this study is to evaluate the analytical characteristics of the nephelometric method used to measure TTR and Retinol binding protein 4 (RBP4).
Methods: paired serum (S) and plasma lithium heparin (Li-ep) samples from healthy subjects and patients with ATTR-CA were collected. Reproducibility analysis, based on the CSLI EP05-A3 protocol, was conducted using S and Li-ep pools where TTR and RBP4 were measured on the automated system Atellica NEPH 630 (Siemens Healthineers). S and Li-ep pools were analysed also by a native electrophoresis on 4-20% polyacrylamide gel associated with western-blot for TTR and RBP4.
Results: no differences were observed in the measurement of TTR and RBP4 in Li-ep and S. The nephelometric method had a similar analytical performance in both matrices (CV% repeatability Li-ep and S: TTR 1.92 and 2.52; RBP4 2.25 and 1.49; CV% within lab-precision: TTR 2.40 and 2.90; RBP4 2.30 and 2.14). Electrophoresis highlighted the presence of high molecular weight forms, TTR tetramers bound to 1 or 2 RBP4 and TTR trimers and dimers in both matrices.
Conclusion: measurement of circulating TTR and RBP4 can be performed on both Li-ep and S. The evaluation of the nephelometric assay showed suitable performances to use it in the clinical context of ATTR-CA. Electrophoretic investigations revealed the presence of several TTR circulating forms, thus further studies are necessary to understand which one is quantified by nephelometry.

BIBLIOGRAFIA

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
2. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 2019;73:2872-91.
3. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, Amyloid 2003;10:160-84.
4. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014;21:221-4.
5. Sant’Anna R, Almeida MR, Varejāo N, Gallego P, Esperante S, Ferreira P, et al. Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Sci Rep 2017;7:44709.
6. Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev 2015;20:117-24.
7. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016;387:2641-54
8. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010;52:347-61.. Erratum in: Prog Cardiovasc Dis 2010;52:445-7.
9. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398-408.
10. Buxbaum JN, Reixach N. Transthyretin: the servant of many masters. Cell Mol Life Sci 2009;66:3095-101.
11. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 2012;421:185-203.
12. Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992;31:8654-60.
13. Yee AW, Aldeghi M, Blakeley MP, Ostermann A, Mas PJ, Moulin M, et al. A molecular mechanism for transthyretin amyloidogenesis. Nat Commun 2019;10:925.
14. Sanguinetti C, Minniti M, Susini V, Caponi L, Panichella G, Castiglione V, et al. The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism. Biomedicine. 2022;10:1906.
15. Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. ATTRibute-CM Investigators. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Me. 2024;390:132-42.
16. Hyung SJ, Deroo S, Robinson CV. Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex. ACS Chem Biol 2010;5:1137-46.
17. Liz MA, Mar FM, Franquinho F, Sousa MM. Aboard transthyretin: From transport to cleavage. IUBMB Life 2010;62:429-35.
18. Hanson JLS, Arvanitis M, Koch CM, Berk JL, Ruberg FL, Prokaeva T, et al. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circ Heart Fail 2018;11:e004000.
19. Buxbaum J, Koziol J, Connors LH. Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. Amyloid 2008;15:255-61.
20. Buxbaum J, Anan I, Suhr O. Serum transthyretin levels in Swedish TTR V30M carriers. Amyloid 2010;17:83-5.
21. Chu X, Wang M, Tang R, Huang Y, Yu J, Cao Y, et al. Clinical and biochemical characterization of hereditary transthyretin amyloidosis caused by E61K mutation. Front Mol Neurosci 2022;15:1003303.
22. Emdin M, Aimo A, Rapezzi C, Fontana M, Perfetto F, Seferović PM, et al. Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J 2019;40:3699-706.
23. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554-68.
24. Gonzalez-Lopez E, Escobar-Lopez L, Obici L, Saturi G, Bezard M, Saith SE, et al. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms. JACC CardioOncol 2022;4:442-54.
25. Falk RH, Haddad M, Walker CR, Dorbala S, Cuddy SAM. Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy. JACC CardioOncol 2021;3:580-6.
26. Judge DP, Heitner SB, Falk RH, Maurer MS, Shah SJ, Witteles RM, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74:285-95.
27. Bulletin 11540511-IT Rev. 06, 2021-10, Siemens Healthineers.
28. Donini LM, Savina C, Ricciardi LM, Coletti C, Paolini M, Scavone L, et al. Predicting the outcome of artificial nutrition by clinical and functional indices. Nutrition 2009;25:11-9.
29. Sergi G, Coin A, Enzi G, Volpato S, Inelmen EM, Buttarello M, et al. Role of visceral proteins in detecting malnutrition in the elderly. Eur J Clin Nutr 2006;60:203-9.
30. Clinical Laboratory Standards Institute (CLSI). Evaluation of precision of quantitative measurement procedures; approved guidelines, third edition. CLSI EP05-A3. CLSI Wayne, PA, 2014.
31. Ruberg FL, Maurer MS. Cardiac Amyloidosis Due to Transthyretin Protein: A Review. JAMA 2024;331:778-91.
32. Castiglione V, Franzini M, Aimo A, Carecci A, Lombardi CM, Passino C, et al. Use of biomarkers to diagnose and manage cardiac amyloidosis. Eur J Heart Fail 2021;23:217-30.
33. Goel V, Gosselin NH, Jomphe C, Zhang X, Marier J-F, Robbie GJ. Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration. Nucleic Acid Ther 2020;30:143-52.
34. Habtemariam BA, Karsten V, Attarwala H, Goel V, Melch M, Clausen VA, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting n-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther 2021;109:372–82.
35. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med 2018;379:22-3.
36. Fox JC, Hellawell JL, Rao S, O’Reilly T, Lumpkin R, Jernelius J, et al. First in human study of ag10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: a phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers. Clin Pharmacol Drug Dev 2020;9:115-29.
37. Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992;31:8654-60.
38. Foss TR, Wiseman RL, Kelly JW. The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry 2005;44:15525-33.
39. Dasari AKR, Hughes RM, Wi S, Hung I, Gan Z, Kelly JW, et al. Transthyretin Aggregation Pathway toward the Formation of Distinct Cytotoxic Oligomers. Sci Rep 2019;9:33.
40. Hyung SJ, Deroo S, Robinson CV. Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex. ACS Chem Bio. 2010;5:1137-46.
41. Raghu P, Sivakumar B. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis. Biochim Biophys Acta 2004;1703:1-9.